Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase
John T. Sisko(United States Military Academy), George D. Hartman(Joint BioEnergy Institute), Xianzhi Mao(United States Military Academy), Kenneth A. Thomas(United States Military Academy), Jennifer M. Shipman(Johns Hopkins University), Nancy E. Kohl(United States Military Academy), Cynthia Miller‐Stein(United States Military Academy), Keith Rickert(United States Military Academy), Timothy J. Koester(United States Military Academy), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Kathleen Coll(United States Military Academy), Mark T. Bilodeau(Kettering University), W. Wayt Gibbs(United States Military Academy), Joseph J. Lynch(United States Military Academy), Carolyn A. Buser(United States Military Academy), Leonard D. Rodman(United States Military Academy), Bradley K. Wong(United States Military Academy), Thomas J. Tucker(MACOM (United States)), Christine Fernandes(United States Military Academy), Patrice A. Ciecko(United States Military Academy)
Cited by 35
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues
|Journal of the American Chemical Society|1999|463
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
|Cancer Immunology Research|2015|440
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
|Proceedings of the National Academy of Sciences|1996|409